Synaptogenix (OCTMKTS: SNPX) is a clinical-stage biopharmaceutical company that has historically worked to develop novel neuro-regenerative drug therapies for neurodegenerative diseases. Synaptogenix has conducted clinical and preclinical studies of its lead therapeutic candidate, Bryostatin-1, in Alzheimer's disease ("AD"), and preclinical studies for rare diseases such as Fragile X syndrome, as well as multiple sclerosis, autistic spectrum disorder, and traumatic brain injury. Bryostatin-1 has already undergone testing in more than 1,600 people in cancer and AD studies, thus creating a large safety data base that will further inform clinical trial designs.C
President & Chief Scientific Officer
Dr. Daniel Alkon, M.D. has spent the past 30 years directing programs on the molecular and structural basis of associative memory at the National Neurologic Institute of NIH and is a Founding Scientific Director of the Blanchette Rockefeller Neuroscience Institute. He and his teams developed neurorestorative therapeutics for degenerative disorders of the central nervous system, as well as non-invasive Biomarkers for Alzheimer’s Disease. Dr. Alkon has also served as the Toyota Chair of Neurodegenerative Diseases, Professor of Neurology at West Virginia University, and was a Research Professor at Johns Hopkins University. Dr. Alkon received his B.A. from the University of Pennsylvania, his M.D. at Cornell University, and was trained in Medicine at Mount Sinai Hospital in New York.